Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting
09 May 2022 - 10:30PM
Delcath Systems, Inc. (Nasdaq:
DCTH), an
interventional oncology company focused on the treatment of primary
and metastatic cancers of the liver, today announced the acceptance
of a poster presentation at the upcoming American Society of
Clinical Oncology (ASCO) 2022 Annual Meeting, to be held in-person
on June 3-7, 2022, in Chicago, Illinois.
Title: FOCUS Phase 3 Trial Results:
Percutaneous Hepatic Perfusion (PHP) With Melphalan for Patients
With Ocular Melanoma Liver Metastases
(PHP-OCM-301/301A)Session
Title: Melanoma/Skin Cancers Session Date and
Time: June 6, 2022, 1:15-4:15 PM CDT (Display) and
4:30-6:30 PM CDT (Discussion)Abstract
Number: 9510Presenter: Dr.
Jonathan Zager, Director of Regional Therapies and Chief Academic
Officer, Moffitt Cancer Center; Professor and Chair, Department of
Oncologic Sciences, USF Morsani School of Medicine
For more information, visit the ASCO Annual
Meeting website.
The poster will be available at
https://delcath.com/investors/events-presentations/ when the ASCO
embargo is released on May 26, 2022, at 4:00 PM CDT.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The company’s proprietary percutaneous hepatic perfusion (PHP)
system is designed to administer high-dose chemotherapy to the
liver while controlling systemic exposure and associated side
effects. In the United States, the PHP system is being developed
under the tradename HEPZATO KIT (melphalan hydrochloride for
injection/hepatic delivery system), or HEPZATO, for the treatment
of patients with unresectable hepatic-dominant metastatic ocular
melanoma (mOM), also known as metastatic uveal melanoma (mUM) and
is considered a combination drug and device product regulated by
the United States Food and Drug Administration (FDA).
In Europe, the PHP system is now regulated as a Class lll
medical device and is approved for sale under the trade name
CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where
it has been used at major medical centers to treat a wide range of
cancers of the liver.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James
Carbonara(646)-755-7412james@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jul 2023 to Jul 2024